Cell News and Research

RSS

WPI researchers receive NIH grant to develop cell therapies for healing cardiac muscle

The National Institutes of Health (NIH) has awarded a five-year, $1.94 million grant to a biomedical research team at Worcester Polytechnic Institute (WPI) working at the forefront of cell therapies for healing cardiac muscle damaged by heart attack or chronic disease.

29 Aug 2013

Tumor vessel density linked to mRCC treatment response

Changes in tumor vessel density correlate with response and resistance to anti-angiogenic therapy in patients with metastatic renal cell carcinoma, study findings suggest.

28 Aug 2013

Muscle density improves mRCC prognosis prediction

Patients with metastatic renal cell carcinoma treated with targeted therapies have a better prognosis if they also have a high quality of muscle, study findings indicate.

28 Aug 2013

Time to RCC recurrence prognostic threshold challenged

A large study confirms the prognostic value of time to recurrence after surgery for renal cell carcinoma, and also suggests the need to reduce the threshold for early recurrence.

28 Aug 2013

Findings support partial nephrectomy for T1b RCC

Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.

28 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Study paves way for understanding the crucial role of lncRNA in human neurons

Scientists at A*STAR's Genome Institute of Singapore have discovered an unusual gene that controls the generation of neurons. This important finding, which is crucial in understanding serious diseases of the brain such as Alzheimer's disease, was reported in the 8th August 2013 issue of the prestigious scientific journal, Molecular Cell.

28 Aug 2013

Researchers suggest new therapeutic target for brain tumor

Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas — the most common form of brain tumor — suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.

28 Aug 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

URI professor studies rare hereditary disorder Fanconi anemia in children

When 2-year-old Logan Stevenson served as best man at his parents' wedding just days before he died of a rare genetic disorder, it drew international attention to a disease about which few people had ever heard. Hearing about Logan's story added another level of urgency to the research being conducted by University of Rhode Island Associate Professor Niall Howlett.

28 Aug 2013

Researchers develop ddPCR technology to quantify rejection biomarker in organ transplant injury

A recently reported blood test for the early detection of organ transplant injury could enable more timely therapeutic intervention in transplant patients and thus help to avoid longer term damage. As described by scientists at the University Medical Center G-ttingen and Chronix Biomedical, a molecular diagnostics company, the new method uses Bio-Rad Laboratories' Droplet Digital PCR (ddPCR-) technology to overcome the obstacles of earlier tests, which were both time-consuming and costly.

28 Aug 2013

Study shows ABL kinases have enhanced expression and activity in CML

Chronic Myelogenous Leukemia (CML) is a cancer of the white blood cells that is most commonly found in adults and in the elderly. Its incidence has been estimated to be 1 to 2 in 100,000 people. CML was the first cancer to be associated with a genetic abnormality, known as the Philadelphia Chromosome, which 95% of all CML patients carry in their cells.

28 Aug 2013

Study shows genetic test to classify gastric cancers and match them to therapies offer best outcomes

Stomach cancer, one of the leading causes of cancer death worldwide, actually falls into three broad subtypes that respond differently to currently available therapies, according to researchers at Duke-NUS Graduate Medical School Singapore.

28 Aug 2013

'Helper cells' improve survival rate of transplanted stem cells, finds study

Like volunteers handing out cups of energy drinks to marathon runners, specially engineered "helper cells" transplanted along with stem cells can dole out growth factors to increase the stem cells' endurance, at least briefly, Johns Hopkins researchers report.

28 Aug 2013

Study: Apoptosis triggers alternate replication pathway in HHV

Washington, DC-Researchers from Children's National Medical Center have found that an alternate, "escape" replication process triggered by apoptosis-the process of cell death or "cell suicide"-appears to be common in human herpesviruses (HHV).

28 Aug 2013

New compound offers way to treat migraine and other disorders of central nervous system

For many migraine sufferers, bright lights are a surefire way to exacerbate their headaches. And for some night-shift workers, just a stroll through a brightly lit parking lot during the morning commute home can be enough to throw off their body's daily rhythms and make daytime sleep nearly impossible. But a new molecule that selectively blocks specialized light-sensitive receptors in the eyes could help both these groups of people, without affecting normal vision.

28 Aug 2013

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors.

From Cell Signaling Technology 28 Aug 2013

Haplogen, Cemm Offer Huge Collection Of Mutant Cell Lines

...

27 Aug 2013

Novel Parkinson’S Target Uncovered

Researchers from Johns Hopkins and the National Cancer Institute (NCI) highlighted a novel mechanism underlying Parkinson's disease while simultaneously putting to rest a previously held theory regarding progression of the disorder. They also identified a compound that alleviates the disease's symptoms in mice.

27 Aug 2013